+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Cancer Supportive Care Drugs Market by Drug Class, Indication, Distribution Channel, End User, Route Of Administration - Global Forecast to 2030- Product Image
Cancer Supportive Care Drugs Market by Drug Class, Indication, Distribution Channel, End User, Route Of Administration - Global Forecast to 2030- Product Image
Sale

Cancer Supportive Care Drugs Market by Drug Class, Indication, Distribution Channel, End User, Route Of Administration - Global Forecast to 2030

  • PDF Icon

    Report

  • 196 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6010628
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The cancer supportive care drugs market is evolving rapidly, driven by innovations in patient management and new care delivery models. Market participants are adapting to address therapy-related side effects, improve patient adherence, and align with shifting payer expectations in oncology. This report equips senior decision-makers with strategic insights for navigating the next phase of supportive care drug development and commercialization.

Market Snapshot: Cancer Supportive Care Drugs Market

The Cancer Supportive Care Drugs Market grew from USD 21.46 billion in 2024 to USD 22.46 billion in 2025. It is expected to continue growing at a CAGR of 4.57%, reaching USD 28.07 billion by 2030.

Scope & Segmentation

This research delivers a multidimensional analysis across the cancer supportive care drugs market, highlighting major drugs, clinical applications, distribution points, and administration routes.

  • Drug Classes: Antiemetics (including 5-HT3 antagonists like granisetron and ondansetron, and NK1 antagonists such as aprepitant), Bone-Modifying Agents (comprising bisphosphonates—pamidronate, zoledronic acid—and RANKL inhibitors like denosumab), Erythropoiesis Stimulating Agents (darbepoetin alfa, epoetin alfa), Growth Factors (filgrastim, pegfilgrastim), Pain Management Agents (NSAIDs like diclofenac and opioids such as fentanyl and morphine).
  • Indications: Bone metastases–related events, cancer-related anemia (non-transfusion-dependent and transfusion-dependent), acute and chronic cancer-related pain, chemotherapy-induced nausea and vomiting (both acute and delayed), and chemotherapy-induced neutropenia (febrile and non-febrile).
  • Distribution Channels: Hospital pharmacies (inpatient and outpatient), online pharmacies, retail pharmacies, and specialty pharmacies.
  • End Users: Clinics, home healthcare providers, and hospitals.
  • Routes of Administration: Intravenous, oral (capsules and tablets), and subcutaneous.
  • Geographic Coverage: Americas (notably the United States with states like California, Texas, New York, Florida, Illinois, Pennsylvania, and Ohio, plus Canada, Mexico, Brazil, Argentina); Europe, Middle East & Africa (including the United Kingdom, Germany, France, and key countries across regions); Asia-Pacific (covering China, India, Japan, Australia, South Korea, and Southeast Asia).
  • Corporate Landscape: Leading entities include Amgen, Novartis, Pfizer, F. Hoffmann-La Roche, Johnson & Johnson, Sanofi, GlaxoSmithKline, Teva Pharmaceuticals, Viatris, and Fresenius Kabi.

Key Takeaways for Decision-Makers

  • Precision medicine principles, including genomic profiling and biomarker-driven strategies, are influencing prophylactic and therapeutic interventions across oncology supportive care.
  • Biosimilars are expanding access and intensifying competition, especially in hematopoietic growth factors and monoclonal antibodies, while pushing organizations to innovate around pricing and supply chain models.
  • Digital health and telemedicine platforms now underpin real-time symptom monitoring, adherence tracking, and remote supportive intervention, shifting care delivery well beyond traditional clinical settings.
  • Patient-centric approaches and less invasive administration routes (oral and subcutaneous) are gaining adoption with tangible impacts on treatment workflows and patient satisfaction.
  • Manufacturers, distributors, and technology partners are building integrated solutions that combine drug therapy, digital tools, and care services, reshaping operational and therapeutic strategies.
  • Regional market dynamics—driven by regulatory differences, reimbursement frameworks, and health system maturity—present both challenges and tailored growth opportunities worldwide.

Cancer Supportive Care Drugs Market: Tariff Impact Analysis

Recent U.S. tariff changes affecting active pharmaceutical ingredients and finished drugs have altered input costs across the cancer supportive care drugs market. The impact is acute in compound-intensive classes such as antiemetics and bone-modifying agents. Supply chain stakeholders are responding by diversifying sourcing geographies, renegotiating procurement models, and leveraging alternative manufacturing partnerships. Downstream, hospital, retail, and online pharmacy channels have adopted new risk-sharing and tiered pricing arrangements to ensure access, while payer organizations intensify reviews of biosimilar alternatives and value-based contracts. Overall, supply chain agility and cost management have become central priorities in response to these tariff policies, ensuring stable access for high-need patient groups despite economic headwinds.

Methodology & Data Sources

This cancer supportive care drugs market research leverages in-depth primary interviews with oncology clinicians, pharmacists, payers, and distribution executives, complemented by quantitative surveys of procurement specialists. Secondary sources include peer-reviewed literature, regulatory filings, company financials, and international health agency reports. Rigorous validation—cross-segmentation, benchmarking, and peer review—fortifies every data point and insight for accuracy and relevance.

Why This Report Matters

  • Supports executive-level planning with actionable intelligence on evolving technologies, regulatory shifts, and key therapeutic trends in cancer supportive care.
  • Reveals the implications of new pricing pressures, emerging therapies, and supply chain adaptations for organizational strategy.
  • Facilitates competitive positioning and stakeholder collaboration through granular segmentation and comprehensive regional analysis.

Conclusion

This executive summary distills critical developments, regulatory shifts, and technology trends defining the future of cancer supportive care drugs. Leaders can leverage these findings to inform resilient strategy, operational alignment, and sustainable growth in this dynamic sector.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Cancer Supportive Care Drugs Market, by Drug Class
8.1. Introduction
8.2. Antiemetics
8.2.1. 5-HT3 Antagonists
8.2.1.1. Granisetron
8.2.1.2. Ondansetron
8.2.2. NK1 Antagonists
8.2.2.1. Aprepitant
8.3. Bone-Modifying Agents
8.3.1. Bisphosphonates
8.3.1.1. Pamidronate
8.3.1.2. Zoledronic Acid
8.3.2. RANKL Inhibitors
8.3.2.1. Denosumab
8.4. Erythropoiesis Stimulating Agents
8.4.1. Darbepoetin Alfa
8.4.2. Epoetin Alfa
8.5. Growth Factors
8.5.1. Filgrastim
8.5.2. Pegfilgrastim
8.6. Pain Management Agents
8.6.1. NSAIDs
8.6.1.1. Diclofenac
8.6.2. Opioids
8.6.2.1. Fentanyl
8.6.2.2. Morphine
9. Cancer Supportive Care Drugs Market, by Indication
9.1. Introduction
9.2. Bone Metastases Related Events
9.3. Cancer-Related Anemia
9.3.1. Non-Transfusion-Dependent
9.3.2. Transfusion-Dependent
9.4. Cancer-Related Pain
9.4.1. Acute Pain
9.4.2. Chronic Pain
9.5. Chemotherapy-Induced Nausea & Vomiting
9.5.1. Acute
9.5.2. Delayed
9.6. Chemotherapy-Induced Neutropenia
9.6.1. Febrile Neutropenia
9.6.2. Non-Febrile Neutropenia
10. Cancer Supportive Care Drugs Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacies
10.2.1. Inpatient
10.2.2. Outpatient
10.3. Online Pharmacies
10.4. Retail Pharmacies
10.5. Specialty Pharmacies
11. Cancer Supportive Care Drugs Market, by End User
11.1. Introduction
11.2. Clinics
11.3. Home Healthcare
11.4. Hospitals
12. Cancer Supportive Care Drugs Market, by Route Of Administration
12.1. Introduction
12.2. Intravenous
12.3. Oral
12.3.1. Capsules
12.3.2. Tablets
12.4. Subcutaneous
13. Americas Cancer Supportive Care Drugs Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Cancer Supportive Care Drugs Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Cancer Supportive Care Drugs Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Amgen Inc.
16.3.2. Novartis AG
16.3.3. Pfizer Inc.
16.3.4. F. Hoffmann-La Roche Ltd
16.3.5. Johnson & Johnson
16.3.6. Sanofi S.A.
16.3.7. GlaxoSmithKline plc
16.3.8. Teva Pharmaceuticals USA, Inc.
16.3.9. Viatris Inc.
16.3.10. Fresenius Kabi AG
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. CANCER SUPPORTIVE CARE DRUGS MARKET MULTI-CURRENCY
FIGURE 2. CANCER SUPPORTIVE CARE DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. CANCER SUPPORTIVE CARE DRUGS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 16. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. CANCER SUPPORTIVE CARE DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. CANCER SUPPORTIVE CARE DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. CANCER SUPPORTIVE CARE DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY 5-HT3 ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY GRANISETRON, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ONDANSETRON, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY 5-HT3 ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NK1 ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APREPITANT, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NK1 ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BONE-MODIFYING AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BISPHOSPHONATES, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PAMIDRONATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ZOLEDRONIC ACID, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BISPHOSPHONATES, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY RANKL INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DENOSUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY RANKL INHIBITORS, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BONE-MODIFYING AGENTS, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DARBEPOETIN ALFA, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY EPOETIN ALFA, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY GROWTH FACTORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY FILGRASTIM, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PEGFILGRASTIM, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY GROWTH FACTORS, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PAIN MANAGEMENT AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NSAIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DICLOFENAC, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NSAIDS, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY FENTANYL, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MORPHINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PAIN MANAGEMENT AGENTS, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BONE METASTASES RELATED EVENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER-RELATED ANEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NON-TRANSFUSION-DEPENDENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY TRANSFUSION-DEPENDENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER-RELATED ANEMIA, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER-RELATED PAIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ACUTE PAIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHRONIC PAIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER-RELATED PAIN, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA & VOMITING, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ACUTE, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DELAYED, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA & VOMITING, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY FEBRILE NEUTROPENIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NON-FEBRILE NEUTROPENIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INPATIENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY OUTPATIENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 72. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 73. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 74. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 75. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 76. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 77. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 78. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY 5-HT3 ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NK1 ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BONE-MODIFYING AGENTS, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BISPHOSPHONATES, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY RANKL INHIBITORS, 2018-2030 (USD MILLION)
TABLE 86. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, 2018-2030 (USD MILLION)
TABLE 87. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY GROWTH FACTORS, 2018-2030 (USD MILLION)
TABLE 88. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PAIN MANAGEMENT AGENTS, 2018-2030 (USD MILLION)
TABLE 89. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NSAIDS, 2018-2030 (USD MILLION)
TABLE 90. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 91. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 92. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER-RELATED ANEMIA, 2018-2030 (USD MILLION)
TABLE 93. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER-RELATED PAIN, 2018-2030 (USD MILLION)
TABLE 94. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA & VOMITING, 2018-2030 (USD MILLION)
TABLE 95. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, 2018-2030 (USD MILLION)
TABLE 96. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 97. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 98. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 99. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 100. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 101. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 102. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 103. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, 2018-2030 (USD MILLION)
TABLE 104. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY 5-HT3 ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 105. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NK1 ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 106. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BONE-MODIFYING AGENTS, 2018-2030 (USD MILLION)
TABLE 107. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BISPHOSPHONATES, 2018-2030 (USD MILLION)
TABLE 108. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY RANKL INHIBITORS, 2018-2030 (USD MILLION)
TABLE 109. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, 2018-2030 (USD MILLION)
TABLE 110. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY GROWTH FACTORS, 2018-2030 (USD MILLION)
TABLE 111. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PAIN MANAGEMENT AGENTS, 2018-2030 (USD MILLION)
TABLE 112. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NSAIDS, 2018-2030 (USD MILLION)
TABLE 113. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 114. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 115. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER-RELATED ANEMIA, 2018-2030 (USD MILLION)
TABLE 116. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER-RELATED PAIN, 2018-2030 (USD MILLION)
TABLE 117. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA & VOMITING, 2018-2030 (USD MILLION)
TABLE 118. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, 2018-2030 (USD MILLION)
TABLE 119. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 120. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 121. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 122. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 123. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 124. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 125. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 126. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, 2018-2030 (USD MILLION)
TABLE 127. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY 5-HT3 ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 128. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NK1 ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 129. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BONE-MODIFYING AGENTS, 2018-2030 (USD MILLION)
TABLE 130. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BISPHOSPHONATES, 2018-2030 (USD MILLION)
TABLE 131. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY RANKL INHIBITORS, 2018-2030 (USD MILLION)
TABLE 132. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, 2018-2030 (USD MILLION)
TABLE 133. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY GROWTH FACTORS, 2018-2030 (USD MILLION)
TABLE 134. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PAIN MANAGEMENT AGENTS, 2018-2030 (USD MILLION)
TABLE 135. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NSAIDS, 2018-2030 (USD MILLION)
TABLE 136. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 137. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 138. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER-RELATED ANEMIA, 2018-2030 (USD MILLION)
TABLE 139. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER-RELATED PAIN, 2018-2030 (USD MILLION)
TABLE 140. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA & VOMITING, 2018-2030 (USD MILLION)
TABLE 141. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, 2018-2030 (USD MILLION)
TABLE 142. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 143. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 144. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 145. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 146. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 147. MEXICO CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 148. MEXICO CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, 2018-2030 (USD MILLION)
TABLE 149. MEXICO CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY 5-HT3 ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 150. MEXICO CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NK1 ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 151. MEXICO CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BONE-MODIFYING AGENTS, 2018-2030 (USD MILLION)
TABLE 152. MEXICO CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BISPHOSPHONATES, 2018-2030 (USD MILLION)
TABLE 153. MEXICO CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY RANKL INHIBITORS, 2018-2030 (USD MILLION)
TABLE 154. MEXICO CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, 2018-2030 (USD MILLION)
TABLE 155. MEXICO CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY GROWTH FACTORS, 2018-2030 (USD MILLION)
TABLE 156. MEXICO CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PAIN MANAGEMENT AGENTS, 2018-2030 (USD MILLION)
TABLE 157. MEXICO CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NSAIDS, 2018-2030 (USD MILLION)
TABLE 158. MEXICO CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 159. MEXICO CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 160. MEXICO CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER-RELATED ANEMIA, 2018-2030 (USD MILLION)
TABLE 161. MEXICO CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER-RELATED PAIN, 2018-2030 (USD MILLION)
TABLE 162. MEXICO CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA & VOMITING, 2018-2030 (USD MILLION)
TABLE 163. MEXICO CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, 2018-2030 (USD MILLION)
TABLE 164. MEXICO CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 165. MEXICO CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 166. MEXICO CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 167. MEXICO CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 168. MEXICO CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 169. BRAZIL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 170. BRAZIL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, 2018-2030 (USD MILLION)
TABLE 171. BRAZIL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY 5-HT3 ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 172. BRAZIL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NK1 ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 173. BRAZIL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BONE-MODIFYING AGENTS, 2018-2030 (USD MILLION)
TABLE 174. BRAZIL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BISPHOSPHONATES, 2018-2030 (USD MILLION)
TABLE 175. BRAZIL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY RANKL INHIBITORS, 2018-2030 (USD MILLION)
TABLE 176. BRAZIL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, 2018-2030 (USD MILLION)
TABLE 177. BRAZIL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY GROWTH FACTORS, 2018-2030 (USD MILLION)
TABLE 178. BRAZIL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PAIN MANAGEMENT AGENTS, 2018-2030 (USD MILLION)
TABLE 179. BRAZIL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NSAIDS, 2018-2030 (USD MILLION)
TABLE 180. BRAZIL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 181. BRAZIL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 182. BRAZIL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER-RELATED ANEMIA, 2018-2030 (USD MILLION)
TABLE 183. BRAZIL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER-RELATED PAIN, 2018-2030 (USD MILLION)
TABLE 184. BRAZIL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA & VOMITING, 2018-2030 (USD MILLION)
TABLE 185. BRAZIL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, 2018-2030 (USD MILLION)
TABLE 186. BRAZIL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 187. BRAZIL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 188. BRAZIL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 189. BRAZIL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 190. BRAZIL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 191. ARGENTINA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 192. ARGENTINA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, 2018-2030 (USD MILLION)
TABLE 193. ARGENTINA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY 5-HT3 ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 194. ARGENTINA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NK1 ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 195. ARGENTINA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BONE-MODIFYING AGENTS, 2018-2030 (USD MILLION)
TABLE 196. ARGENTINA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BISPHOSPHONATES, 2018-2030 (USD MILLION)
TABLE 197. ARGENTINA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY RANKL INHIBITORS, 2018-2030 (USD MILLION)
TABLE 198. ARGENTINA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, 2018-2030 (USD MILLION)
TABLE 199. ARGENTINA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY GROWTH FACTORS, 2018-2030 (USD MILLION)
TABLE 200. ARGENTINA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PAIN MANAGEMENT AGENTS, 2018-2030 (USD MILLION)
TABLE 201. ARGENTINA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NSAIDS, 2018-2030 (USD MILLION)
TABLE 202. ARGENTINA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 203. ARGENTINA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 204. ARGENTINA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER-RELATED ANEMIA, 2018-2030 (USD MILLION)
TABLE 205. ARGENTINA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER-RELATED PAIN, 2018-2030 (USD MILLION)
TABLE 206. ARGENTINA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA & VOMITING, 2018-2030 (USD MILLION)
TABLE 207. ARGENTINA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, 2018-2030 (USD MILLION)
TABLE 208. ARGENTINA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 209. ARGENTINA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 210. ARGENTINA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 211. ARGENTINA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 212. ARGENTINA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 213. EUROPE, MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 214. EUROPE, MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, 2018-2030 (USD MILLION)
TABLE 215. EUROPE, MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY 5-HT3 ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 216. EUROPE, MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NK1 ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 217. EUROPE, MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BONE-MODIFYING AGENTS, 2018-2030 (USD MILLION)
TABLE 218. EUROPE, MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BISPHOSPHONATES, 2018-2030 (USD MILLION)
TABLE 219. EUROPE, MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY RANKL INHIBITORS, 2018-2030 (USD MILLION)
TABLE 220. EUROPE, MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, 2018-2030 (USD MILLION)
TABLE 221. EUROPE, MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY GROWTH FACTORS, 2018-2030 (USD MILLION)
TABLE 222. EUROPE, MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PAIN MANAGEMENT AGENTS, 2018-2030 (USD MILLION)
TABLE 223. EUROPE, MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NSAIDS, 2018-2030 (USD MILLION)
TABLE 224. EUROPE, MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 225. EUROPE, MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 226. EUROPE, MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER-RELATED ANEMIA, 2018-2030 (USD MILLION)
TABLE 227. EUROPE, MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER-RELATED PAIN, 2018-2030 (USD MILLION)
TABLE 228. EUROPE, MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA & VOMITING, 2018-2030 (USD MILLION)
TABLE 229. EUROPE, MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, 2018-2030 (USD MILLION)
TABLE 230. EUROPE, MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 231. EUROPE, MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 232. EUROPE, MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 233. EUROPE, MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 234. EUROPE, MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 235. EUROPE, MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 236. UNITED KINGDOM CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 237. UNITED KINGDOM CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, 2018-2030 (USD MILLION)
TABLE 238. UNITED KINGDOM CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY 5-HT3 ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 239. UNITED KINGDOM CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NK1 ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 240. UNITED KINGDOM CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BONE-MODIFYING AGENTS, 2018-2030 (USD MILLION)
TABLE 241. UNITED KINGDOM CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BISPHOSPHONATES, 2018-2030 (USD MILLION)
TABLE 242. UNITED KINGDOM CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY RANKL INHIBITORS, 2018-2030 (USD MILLION)
TABLE 243. UNITED KINGDOM CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, 2018-2030 (USD MILLION)
TABLE 244. UNITED KINGDOM CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY GROWTH FACTORS, 2018-2030 (USD MILLION)
TABLE 245. UNITED KINGDOM CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PAIN MANAGEMENT AGENTS, 2018-2030 (USD MILLION)
TABLE 246. UNITED KINGDOM CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NSAIDS, 2018-2030 (USD MILLION)
TABLE 247. UNITED KINGDOM CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 248. UNITED KINGDOM CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 249. UNITED KINGDOM CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER-RELATED ANEMIA, 2018-2030 (USD MILLION)
TABLE 250. UNITED KINGDOM CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER-RELATED PAIN, 2018-2030 (USD MILLION)
TABLE 251. UNITED KINGDOM CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA & VOMITING, 2018-2030 (USD MILLION)
TABLE 252. UNITED KINGDOM CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, 2018-2030 (USD MILLION)
TABLE 253. UNITED KINGDOM CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 254. UNITED KINGDOM CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 255. UNITED KINGDOM CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 256. UNITED KINGDOM CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 257. UNITED KINGDOM CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 258. GERMANY CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 259. GERMANY CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, 2018-2030 (USD MILLION)
TABLE 260. GERMANY CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY 5-HT3 ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 261. GERMANY CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NK1 ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 262. GERMANY CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BONE-MODIFYING AGENTS, 2018-2030 (USD MILLION)
TABLE 263. GERMANY CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BISPHOSPHONATES, 2018-2030 (USD MILLION)
TABLE 264. GERMANY CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY RANKL INHIBITORS, 2018-2030 (USD MILLION)
TABLE 265. GERMANY CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, 2018-2030 (USD MILLION)
TABLE 266. GERMANY CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY GROWTH FACTORS, 2018-2030 (USD MILLION)
TABLE 267. GERMANY CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PAIN MANAGEMENT AGENTS, 2018-2030 (USD MILLION)
TABLE 268. GERMANY CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NSAIDS, 2018-2030 (USD MILLION)
TABLE 269. GERMANY CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 270. GERMANY CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 271. GERMANY CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER-RELATED ANEMIA, 2018-2030 (USD MILLION)
TABLE 272. GERMANY CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER-RELATED PAIN, 2018-2030 (USD MILLION)
TABLE 273. GERMANY CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA & VOMITING, 2018-2030 (USD MILLION)
TABLE 274. GERMANY CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, 2018-2030 (USD MILLION)
TABLE 275. GERMANY CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 276. GERMANY CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 277. GERMANY CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 278. GERMANY CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 279. GERMANY CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 280. FRANCE CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 281. FRANCE CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, 2018-2030 (USD MILLION)
TABLE 282. FRANCE CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY 5-HT3 ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 283. FRANCE CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NK1 ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 284. FRANCE CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BONE-MODIFYING AGENTS, 2018-2030 (USD MILLION)
TABLE 285. FRANCE CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BISPHOSPHONATES, 2018-2030 (USD MILLION)
TABLE 286. FRANCE CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY RANKL INHIBITORS, 2018-2030 (USD MILLION)
TABLE 287. FRANCE CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, 2018-2030 (USD MILLION)
TABLE 288. FRANCE CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY GROWTH FACTORS, 2018-2030 (USD MILLION)
TABLE 289. FRANCE CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PAIN MANAGEMENT AGENTS, 2018-2030 (USD MILLION)
TABLE 290. FRANCE CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NSAIDS, 2018-2030 (USD MILLION)
TABLE 291. FRANCE CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 292. FRANCE CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 293. FRANCE CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER-RELATED ANEMIA, 2018-2030 (USD MILLION)
TABLE 294. FRANCE CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER-RELATED PAIN, 2018-2030 (USD MILLION)
TABLE 295. FRANCE CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA & VOMITING, 2018-2030 (USD MILLION)
TABLE 296. FRANCE CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, 2018-2030 (USD MILLION)
TABLE 297. FRANCE CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 298. FRANCE CANCER SUPPORTIVE CARE

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Cancer Supportive Care Drugs market report include:
  • Amgen Inc.
  • Novartis AG
  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd
  • Johnson & Johnson
  • Sanofi S.A.
  • GlaxoSmithKline plc
  • Teva Pharmaceuticals USA, Inc.
  • Viatris Inc.
  • Fresenius Kabi AG

Table Information

Report AttributeDetails
No. of Pages196
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 22.46 Billion
Forecasted Market Value ( USD ) by 2030 $ 28.07 Billion
Compound Annual Growth Rate4.5%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Cancer Supportive Care Drugs Market Report 2025 - Product Image

Cancer Supportive Care Drugs Market Report 2025

  • Report
  • 200 Pages
  • Global
From
2025 Global Forecast for Cancer Supportive Care Drugs (2026-2031 Outlook)-High Tech Outlook Report - Product Image

2025 Global Forecast for Cancer Supportive Care Drugs (2026-2031 Outlook)-High Tech Outlook Report

  • Report
  • 132 Pages
  • Global
From
Cancer Therapeutics & Supportive Care Drugs Market by Drug Type, Mechanism Of Action, Indication, Route Of Administration, Distribution Channel - Global Forecast to 2030 - Product Image

Cancer Therapeutics & Supportive Care Drugs Market by Drug Type, Mechanism Of Action, Indication, Route Of Administration, Distribution Channel - Global Forecast to 2030

  • Report
  • 193 Pages
  • Global
From
Cancer Supportive Care Products Market Report 2025 - Product Image

Cancer Supportive Care Products Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Cancer Supportive Care Market 2024-2028 - Product Image

Cancer Supportive Care Market 2024-2028

  • Report
  • 188 Pages
  • Global
From

About the Cancer Care Market

The Cancer Care market within the context of Oncology Drugs is a rapidly growing industry. It is composed of a variety of products and services, including drugs, diagnostics, and treatments. Oncology drugs are used to treat cancer, and they can be divided into two categories: targeted therapies and immunotherapies. Targeted therapies are designed to target specific cancer cells, while immunotherapies are designed to boost the body's own immune system to fight cancer. Both types of drugs are used to treat a variety of cancers, including breast, lung, and colorectal cancer. The Cancer Care market is highly competitive, with many companies vying for market share. Companies in the market include AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Merck, Novartis, Pfizer, and Roche. These companies are all involved in the development, manufacture, and marketing of oncology drugs. Additionally, there are many smaller companies that specialize in the development of new treatments and therapies. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.